Cite
APA Citation
Keeping, S., Wu, E., Chan, K., Mojebi, A., Ferrante, S. A., & Balakumaran, A. (2018). pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin's lymphoma progressing after brentuximab vedotin: an indirect treatment comparison. Expert review of hematology, 11(6), 503–511. http://access.bl.uk/ark:/81055/vdc_100064996908.0x000009